Verrica Pharmaceuticals Inc (VRCA)
1.44
-0.09
(-5.88%)
USD |
NASDAQ |
Nov 04, 16:00
1.05
-0.39
(-27.08%)
After-Hours: 20:00
Verrica Pharmaceuticals Enterprise Value: 72.26M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 72.26M |
| November 01, 2024 | 76.10M |
| October 31, 2024 | 70.56M |
| October 30, 2024 | 79.09M |
| October 29, 2024 | 82.50M |
| October 28, 2024 | 77.38M |
| October 25, 2024 | 75.25M |
| October 24, 2024 | 74.82M |
| October 23, 2024 | 75.25M |
| October 22, 2024 | 78.66M |
| October 21, 2024 | 77.81M |
| October 18, 2024 | 79.09M |
| October 17, 2024 | 73.12M |
| October 16, 2024 | 75.25M |
| October 15, 2024 | 70.13M |
| October 14, 2024 | 71.41M |
| October 11, 2024 | 68.00M |
| October 10, 2024 | 65.86M |
| October 09, 2024 | 65.44M |
| October 08, 2024 | 65.44M |
| October 07, 2024 | 68.00M |
| October 04, 2024 | 66.72M |
| October 03, 2024 | 72.69M |
| October 02, 2024 | 58.18M |
| October 01, 2024 | 69.28M |
| Date | Value |
|---|---|
| September 30, 2024 | 72.69M |
| September 27, 2024 | 82.93M |
| September 26, 2024 | 82.50M |
| September 25, 2024 | 81.65M |
| September 24, 2024 | 85.92M |
| September 23, 2024 | 85.49M |
| September 20, 2024 | 88.05M |
| September 19, 2024 | 93.60M |
| September 18, 2024 | 89.76M |
| September 17, 2024 | 86.34M |
| September 16, 2024 | 91.46M |
| September 13, 2024 | 94.88M |
| September 12, 2024 | 93.60M |
| September 11, 2024 | 93.17M |
| September 10, 2024 | 94.02M |
| September 09, 2024 | 92.32M |
| September 06, 2024 | 92.32M |
| September 05, 2024 | 99.57M |
| September 04, 2024 | 108.96M |
| September 03, 2024 | 103.84M |
| August 30, 2024 | 111.09M |
| August 29, 2024 | 114.93M |
| August 28, 2024 | 110.24M |
| August 27, 2024 | 115.79M |
| August 26, 2024 | 120.48M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
46.43M
Minimum
Nov 09 2022
414.05M
Maximum
Mar 15 2021
213.62M
Average
211.41M
Median
Nov 24 2020
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 12.24B |
| Elite Pharmaceuticals Inc | 544.19M |
| Eagle Pharmaceuticals Inc | -- |
| TELA Bio Inc | 84.76M |
| Terns Pharmaceuticals Inc | 274.27M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.19M |
| Revenue (Quarterly) | 5.177M |
| Total Expenses (Quarterly) | 20.38M |
| EPS Diluted (Quarterly) | -0.37 |
| Gross Profit Margin (Quarterly) | 89.53% |
| Profit Margin (Quarterly) | -332.0% |
| Earnings Yield | -131.2% |
| Normalized Earnings Yield | -127.45 |